000			01548 a2200445 4500
005			20250513234259.0
264		0	_c20010412
008			200104s 0 0 eng d
022			_a1170-7690
024	7		_a10.2165/00019053-200119001-00005 _2doi
040			_aNLM _beng _cNLM
100	1		_aChancellor, J V
245	0	0	_aEconomic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland. _h[electronic resource]
260			_bPharmacoEconomics _c2001
300			_a59-75 p. _bdigital
500			_aPublication Type: Journal Article; Research Support, Non-U.S. Gov't
650	0	4	_aAnemia _xchemically induced
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xadverse effects
650	0	4	_aAnti-Ulcer Agents _xeconomics
650	0	4	_aArthritis _xdrug therapy
650	0	4	_aCelecoxib
650	0	4	_aClinical Trials as Topic
650	0	4	_aCost of Illness
650	0	4	_aCost-Benefit Analysis
650	0	4	_aCyclooxygenase Inhibitors _xeconomics
650	0	4	_aDecision Trees
650	0	4	_aDrug Therapy, Combination
650	0	4	_aDuodenal Ulcer _xchemically induced
650	0	4	_aEconomics, Pharmaceutical
650	0	4	_aHumans
650	0	4	_aProbability
650	0	4	_aPyrazoles
650	0	4	_aSulfonamides _xeconomics
650	0	4	_aSwitzerland
700	1		_aHunsche, E
700	1		_ade Cruz, E
700	1		_aSarasin, F P
773	0		_tPharmacoEconomics _gvol. 19 Suppl 1 _gp. 59-75
856	4	0	_uhttps://doi.org/10.2165/00019053-200119001-00005 _zAvailable from publisher's website
999			_c11215825 _d11215825